_version_ 1784821574672580608
author Sureda-Balari, Anna
Terol, M. José
Domingo-Domènech, Eva
Rodriguez, Ana Pilar González
Mohedo, Francisca Hernández
Céspedes, Javier Núñez
De La Cruz Vicente, Fátima
Muñoz, Carmen Martínez
Díaz, M. Elena Amutio
Córdoba, Raul
Izquierdo, Antonia Rodríguez
Domínguez, Samuel Romero
Meijide, Javier Briones
Greil, Richard
Velázquez, Miriam Moreno
Rubio, Araceli
Oteiro, Mariana Bastos
Gómez, Pilar
Avivi, Irit
Casanova, María
Del Campo García, Raquel
Noriega, Victor
Blanco, José Javier Sánchez
Sanz, Ramón. García
author_facet Sureda-Balari, Anna
Terol, M. José
Domingo-Domènech, Eva
Rodriguez, Ana Pilar González
Mohedo, Francisca Hernández
Céspedes, Javier Núñez
De La Cruz Vicente, Fátima
Muñoz, Carmen Martínez
Díaz, M. Elena Amutio
Córdoba, Raul
Izquierdo, Antonia Rodríguez
Domínguez, Samuel Romero
Meijide, Javier Briones
Greil, Richard
Velázquez, Miriam Moreno
Rubio, Araceli
Oteiro, Mariana Bastos
Gómez, Pilar
Avivi, Irit
Casanova, María
Del Campo García, Raquel
Noriega, Victor
Blanco, José Javier Sánchez
Sanz, Ramón. García
author_sort Sureda-Balari, Anna
collection PubMed
description
format Online
Article
Text
id pubmed-9621516
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96215162022-11-01 T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. Sureda-Balari, Anna Terol, M. José Domingo-Domènech, Eva Rodriguez, Ana Pilar González Mohedo, Francisca Hernández Céspedes, Javier Núñez De La Cruz Vicente, Fátima Muñoz, Carmen Martínez Díaz, M. Elena Amutio Córdoba, Raul Izquierdo, Antonia Rodríguez Domínguez, Samuel Romero Meijide, Javier Briones Greil, Richard Velázquez, Miriam Moreno Rubio, Araceli Oteiro, Mariana Bastos Gómez, Pilar Avivi, Irit Casanova, María Del Campo García, Raquel Noriega, Victor Blanco, José Javier Sánchez Sanz, Ramón. García Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621516/ http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Relapsed/Refractory
Sureda-Balari, Anna
Terol, M. José
Domingo-Domènech, Eva
Rodriguez, Ana Pilar González
Mohedo, Francisca Hernández
Céspedes, Javier Núñez
De La Cruz Vicente, Fátima
Muñoz, Carmen Martínez
Díaz, M. Elena Amutio
Córdoba, Raul
Izquierdo, Antonia Rodríguez
Domínguez, Samuel Romero
Meijide, Javier Briones
Greil, Richard
Velázquez, Miriam Moreno
Rubio, Araceli
Oteiro, Mariana Bastos
Gómez, Pilar
Avivi, Irit
Casanova, María
Del Campo García, Raquel
Noriega, Victor
Blanco, José Javier Sánchez
Sanz, Ramón. García
T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title_full T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title_fullStr T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title_full_unstemmed T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title_short T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
title_sort t098: brentuximab vedotin plus eshap (breshap) versus eshap in patients with relapsed or refractory classical hodgkin’s lymphoma. interim results of the breselibet prospective clinical trial.
topic Relapsed/Refractory
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621516/
http://dx.doi.org/10.1097/01.HS9.0000890960.29449.17
work_keys_str_mv AT suredabalarianna t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT terolmjose t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT domingodomenecheva t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT rodriguezanapilargonzalez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT mohedofranciscahernandez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT cespedesjaviernunez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT delacruzvicentefatima t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT munozcarmenmartinez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT diazmelenaamutio t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT cordobaraul t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT izquierdoantoniarodriguez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT dominguezsamuelromero t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT meijidejavierbriones t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT greilrichard t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT velazquezmiriammoreno t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT rubioaraceli t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT oteiromarianabastos t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT gomezpilar t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT aviviirit t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT casanovamaria t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT delcampogarciaraquel t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT noriegavictor t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT blancojosejaviersanchez t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial
AT sanzramongarcia t098brentuximabvedotinpluseshapbreshapversuseshapinpatientswithrelapsedorrefractoryclassicalhodgkinslymphomainterimresultsofthebreselibetprospectiveclinicaltrial